At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
-
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.
-
Autologous stem cell transplant (ASCT) is a standard treatment for multiple myeloma. An ASCT replaces the blood-forming cells destroyed by disease or treatment with healthy cells collected from your blood. Before ASCT, people generally receive a standard drug, melphalan, to prepare the body for the transplant.
-
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
-
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
- A Phase 1 Study of ANS03 in People With Advanced Solid Tumors
Full Title A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants with Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Purpose
Researchers want to find the best dose of ANS03 to use and see how well it works in people with solid tumors that metastasized (spread). In addition, their tumors have mutations (changes) in the ROS1 or NTRK1/2/3 genes.
This study includes people with these cancers:
- Non-small cell lung cancer
- Gastric (stomach) cancer
- Breast cancer
- Esophageal cancer
- Pancreatic cancer
- Other types of solid tumors
ANS03 blocks proteins (ROS1 and TRK) that may be too active or found at high levels in your cancer cells. By blocking these proteins, ANS03 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor that cannot be cured with standard therapy.
- Have a tumor with an ROS1 or NTRK1/2/3 gene fusion.
- Have completed prior anti-cancer therapies at least 4 weeks before getting ANS03.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-099Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06716138ClinicalTrials.gov